Related references
Note: Only part of the references are listed.The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion
Ryota Tamura et al.
ENDOCRINE PATHOLOGY (2019)
A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma
Ryogo Kikuchi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Ryota Tamura et al.
CANCER SCIENCE (2019)
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
Ryota Tamura et al.
NATURE COMMUNICATIONS (2019)
Histopathological vascular investigation of the peritumoral brain zone of glioblastomas
Ryota Tamura et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma
Shunsuke Shibao et al.
Oncotarget (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Paradoxical findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
Yohei Yamamoto et al.
ONCOTARGET (2017)
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response
Ryota Tamura et al.
BRAIN TUMOR PATHOLOGY (2017)
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2017)
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
Yasuharu Akasaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Histopathological investigation of glioblastomas resected under bevacizumab treatment
Ryota Tamura et al.
ONCOTARGET (2016)
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Yu -Ling Li et al.
CANCER BIOLOGY & MEDICINE (2016)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome
Shoichi Hazama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Hisae Iinuma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
Shoichi Hazama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
K. Yoshimura et al.
BRITISH JOURNAL OF CANCER (2013)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Toru Masuzawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
Petra Hamerlik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer
Rupal Ramakrishnan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme
John D. Hainsworth et al.
CANCER (2010)
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa et al.
CANCER SCIENCE (2010)
VEGFR2 is selectively expressed by FOXP3(high) CD4(+) Treg
Hiroyuki Suzuki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Jie Ma et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Robert Roskoski
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
Hidenobu Ishizaki et al.
CLINICAL CANCER RESEARCH (2006)
Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2
S Wada et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PD-1 inhibits antiviral immunity at the effector phase in the liver
YH Iwai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas
IH Chaudhry et al.
HISTOPATHOLOGY (2001)
Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors
Y Hirose et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2001)
Share Paper
